摘要
目的:观察他克莫司软膏联合枸地氯雷他定治疗面部特应性皮炎(AD)患者的效果。方法:选取2021年1月至2022年9月该院收治的86例面部AD患者进行前瞻性研究,利用随机数字表法将其分为观察组(n=43)和对照组(n=43)。对照组采用枸地氯雷他定治疗,观察组在对照组基础上联合他克莫司软膏治疗,比较两组临床疗效,治疗前后特应性皮炎积分指数(SCORAD)评分、炎性因子[γ干扰素(IFN-γ)、白细胞介素(IL)-4、IL-17]水平,治疗期间不良反应发生率和随访6个月的复发率。结果:观察组治疗总有效率为97.67%(42/43),高于对照组的81.40%(35/43),差异有统计学意义(P<0.05);治疗1、2、3周后,观察组SCORAD评分均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组IFN-γ水平高于对照组,IL-17、IL-4水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组复发率为9.76%(4/41),低于对照组的37.50%(12/32),差异有统计学意义(P<0.05)。结论:他克莫司软膏联合枸地氯雷他定治疗面部AD患者可提高治疗总有效率,改善炎性因子水平,降低SCORAD评分和复发率,效果优于单纯枸地氯雷他定治疗。
Objective:To observe effects of Tacrolimus ointment combined with Desloratadine citrate disodium in treatment of patients with facial atopic dermatitis(AD).Methods:A prospective study was conducted on 86 patients with facial AD admitted to this hospital from January 2021 to September 2022.They were divided into observation group(n=43)and control group(n=43)by using the random number table method.The control group was treated with Desloratadine citrate disodium,while the observation group was treated with Tacrolimus ointment on the basis of that of the control group.The clinical efficacy,the scoring atopic dermatitis(SCORAD)score,the levels of inflammatory factors[interferon-γ(IFN-γ),interleukin(IL)-4,IL-17]before and after the treatment,the incidence of adverse reactions during the treatment,and the recurrence rate after 6 months of follow-up were compared between the two groups.Results:The total effective rate of the observation group was 97.67%(42/43),which was higher than 81.40%(35/43)of the control group,and the difference was statistically significant(P<0.05).After 1,2 and 3 weeks of treatment,the SCORAD scores of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of IFN-γin the observation group was higher than that in the control group,the levels of IL-17 and IL-4 were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate of the observation group was 9.76%(4/41),which was lower than 37.50%(12/32)of the control group,and the difference was statistically significant(P<0.05).Conclusions:Tacrolimus ointment combined with Desloratadine citrate disodium in the treatment of the facial AD patients can improve the total effective rate of treatment,improve the levels of inflammatory factors,and reduce the SCORAD scores and the recurrence rate.Moreover,it is superior to single Desloratadine citrate disodium treatment.
作者
刘小会
LIU Xiaohui(Department of Dermatology of Luohe Third People’s Hospital,Luohe 462000 Henan,China)
出处
《中国民康医学》
2024年第2期48-50,60,共4页
Medical Journal of Chinese People’s Health
关键词
他克莫司软膏
枸地氯雷他定
面部
特应性皮炎
炎性因子
不良反应
复发率
Tacrolimus ointment
Desloratadine citrate disodium
Facial
Atopic dermatitis
Inflammatory factor
Adverse reaction
Recurrence rate
作者简介
刘小会(1977.05-),女,汉族,河南禹州人,本科,主治医师,研究方向为银屑病、婴幼儿湿疹、皮炎。
